Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: Male

Summary

We hypothesize that paricalcitol and calcitriol in dose-dependent manner are effective for the management of chronic allograft dysfunction (CAD), protection and repair of kidney and heart, management of chronic renocardiac syndrome (CRS). We assume that paricalcitol can have some advantages if compare with calcitriol or cholecalciferol due to absence of calcemic and phosphatemic complications alongside with great beneficial potential.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ural Medical University; Ural State Medical University
• Collaborators: De Haar Research Foundation; Ural Institute of Cardiology
• Treatments: Calcitriol; Cholecalciferol; Ergocalciferols; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• Age 40-75

• Male

• History of chronic kidney disease and cardiorenal syndrome

• Written informed consent

Exclusion Criteria:

• Female

• Acute illness

• Life-threat competitive illness

• Mental disorders

• Endocrinologic diseases (including diabetes mellitus, hyperparathyroidism, and other thyroid disorders)

• Need for dialyses

• Hypercalcemia

• Concomitant use of hormone or cytokine medication

• Participation to any drug-investigation during the previous 60 days as checked with VIP check